|[February 21, 2014]
CordenPharma Switzerland Transfers Amino Acid Building Blocks Portfolio to Chemie Uetikon GmbH
LIESTAL, Switzerland --(Business Wire)--
CordenPharma Switzerland LLC, an Active Pharmaceutical Ingredient
manufacturing facility in Liestal, Switzerland, is pleased to announce a
transfer of their entire Amino Acid Building Blocks product portfolio to CU
Chemie Uetikon GmbH, based in Lahr, Germany, effective February 1,
CordenPharma Switzerland, pioneers of the protected amino acid market,
had identified Chemie Uetikon more than a decade ago as an ideal partner
for larger scale manufacturing of amino acid building blocks. As a
result of the transfer, CordenPharma Switzerland will now focus on
growing its core peptide synthesis and specialized ingredient
manufacturing capabilities such as carbohydrates and synthetic lipids.
Chemie Uetikon will take over the Amino Acid Building Blocks business
from CordenPharma Switzerland and market them to clients globally.
CordenPharma Switzerland will continue to manufacture and market
Pseudoproline Building Blocks using proprietary technology.
Chemie Uetikon has published a new catalog, listing the transferred
portfolio of Amino Acid Building Blocks. This extensive library of
natural and unnatural amino acids with a wide variety of protecting
groups, both at the N- and the C-terminus, can be used for peptide
synthesis in solution and solid-phase from laboratory through commercial
scale. Chemie Uetikon will continue to develop its Amino Acid Building
Blocks portfolio by adding new products on a regular basis.
According to Thomas Seeler, Chemie Uetikon's CFO and COO, "Uetikon has
been a hidden champion of Amino Acid Building Block manufacturing up to
now." Dr. Stefan Peterli, CEO at Chemie Uetikon adds, "We are looking
forward to serving customers globally with Amino Acid Building Blocks of
non-animal, non-human grade, made in German."
Dr. Juerg Burger, CordenPharma Switzerland's CEO comments, "CordenPharma
is developing as a company and peptides are a key area for three of its
API manufacturing facilities - CordenPharma
Switzerland (Liestal, CH), CordenPharma
Colorado (Boulder, CO, USA) and Peptisyntha
(Brussels, BE). We are excited to have Chemie Uetikon as an established
and highly motivated supplier for the company."
CordenPharma, a pharmaceutical brand of International Chemical
Investors Group (ICIG), is a full-service Contract Manufacturing
Organization (CMO) partner in the cGMP Contract Development &
Manufacturing of APIs, Drug Products and associated Packaging Services
for antibiotic / oncological, peptide / injectable and highly potent /
small molecule technology platforms. www.cordenpharma.com.
CordenPharma Switzerland, one of multiple CordenPharma
facilities across Europe and the US, specializes in the development and
small to large-scale manufacturing of APIs, key intermediates, and
specific ingredients such as in synthetic lipids, peptides, complex
carbohydrates, conjugates and pseudoproline dipeptides. www.cordenpharma.com/facilities/switzerland.
CU Chemie Uetikon is a well-established European chemical and
pharmaceutical producer with unique expertise in manufacturing of
generic and innovative Active Pharmaceutical Ingredients (APIs) and a
substantial custom manufacturing business focused on the pharmaceutical
industry. We are globally active, serving hundreds of customers with a
solid track record of manufacturing in state-of-the-art production
facilities under cGMP including a 20-year history of successful FDA
inspections. For more information about Chemie Uetikon, visit www.uetikon.com.
[ Back To Technology News's Homepage ]